|
Human Response
- Vaccination Protocol: Patients were immunized with 1mL of 0.67 mg (low dose), 2 mg (middle dose), or 6 mg (high dose) GLS-5300 on day 1, week 4, and week 12 with co-localized intramuscular electroporation afterwards. (Modjarrad et al., 2019)
- Immune Response: S1-specific and S-specific antibodies were detectable in most patients between first and third doses. Neutralizing antibodies were not maintained through the end of the study (by most participants). IFN-γ detected in all groups. (Modjarrad et al., 2019)
|
Modjarrad et al., 2019: Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. The Lancet. Infectious diseases. 2019; 19(9); 1013-1022. [PubMed: 31351922].
|
